The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti-FVIII antibody.

MLA

Onishi, Tomoko, et al. “The Effects of Emicizumab on in Vitro Coagulation and Fibrinolysis Parameters in Patients with Disseminated Intravascular Coagulation with and without Addition of Anti-FVIII Antibody.” Haemophilia : The Official Journal of the World Federation of Hemophilia, vol. 30, no. 3, May 2024, pp. 836–44. EBSCOhost, https://doi.org/10.1111/hae.14997.

APA

Onishi, T., Shimo, H., Harada, S., & Nogami, K. (2024). The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti-FVIII antibody. Haemophilia : The Official Journal of the World Federation of Hemophilia, 30(3), 836–844. https://doi.org/10.1111/hae.14997

Chicago

Onishi, Tomoko, Hanako Shimo, Suguru Harada, and Keiji Nogami. 2024. “The Effects of Emicizumab on in Vitro Coagulation and Fibrinolysis Parameters in Patients with Disseminated Intravascular Coagulation with and without Addition of Anti-FVIII Antibody.” Haemophilia : The Official Journal of the World Federation of Hemophilia 30 (3): 836–44. doi:10.1111/hae.14997.